GoldenGolden
BioVentures Investors

BioVentures Investors

A private equity and venture capital firm in Massachusetts that focuses on commercial development of advanced technology in life sciences and healthcare.

All edits by  Cole Hudson 

Edits on 19 Mar, 2020
Cole Hudson
Cole Hudson approved a suggestion from Golden's AI on 19 Mar, 2020
Edits made to:
Article (+13/-13 characters)
Article

Bioventures Investors is a private equity and venture capital firm in Massachusetts that focuses on commercial development of advanced technology in life sciences and healthcare. Founded 1998 in Wellesley, Massachusetts, United States by Marc Goldberg, it invests in early stage ventures and late stage ventures. Its portfolio companies include Sonomotion, Kanova, Endotronix, POC Medical Systems, Nano-Micro Technology, Cylene Pharmaceuticals, Claros Diagnostics, Hydra Biosciences, and Biolex Therapeutics. As of March 2020, Bioventures Investors has made 32 investments. Their most recent investment was on November 12, 2019, when Sonomotion raised $10M. Bioventures Investors has had seven exits, the most notable of which include Enanta Pharmaceuticals, Phase ForwardPhase Forward, and Spirus Medical. The company has raised a single venture fund, BioVentures Investors IV. This fund was announced on October 10, 2016 and raised a total of $87M.

Cole Hudson
Cole Hudson approved a suggestion from Golden's AI on 19 Mar, 2020
Edits made to:
Article (+22/-22 characters)
Article

Bioventures Investors is a private equity and venture capital firm in Massachusetts that focuses on commercial development of advanced technology in life sciences and healthcare. Founded 1998 in Wellesley, Massachusetts, United States by Marc Goldberg, it invests in early stage ventures and late stage ventures. Its portfolio companies include Sonomotion, Kanova, Endotronix, POC Medical Systems, Nano-Micro Technology, Cylene PharmaceuticalsCylene Pharmaceuticals, Claros Diagnostics, Hydra Biosciences, and Biolex Therapeutics. As of March 2020, Bioventures Investors has made 32 investments. Their most recent investment was on November 12, 2019, when Sonomotion raised $10M. Bioventures Investors has had seven exits, the most notable of which include Enanta Pharmaceuticals, Phase Forward, and Spirus Medical. The company has raised a single venture fund, BioVentures Investors IV. This fund was announced on October 10, 2016 and raised a total of $87M.

Cole Hudson
Cole Hudson approved a suggestion from Golden's AI on 19 Mar, 2020
Edits made to:
Article (+10/-10 characters)
Article

Bioventures Investors is a private equity and venture capital firm in Massachusetts that focuses on commercial development of advanced technology in life sciences and healthcare. Founded 1998 in Wellesley, Massachusetts, United States by Marc Goldberg, it invests in early stage ventures and late stage ventures. Its portfolio companies include Sonomotion, Kanova, EndotronixEndotronix, POC Medical Systems, Nano-Micro Technology, Cylene Pharmaceuticals, Claros Diagnostics, Hydra Biosciences, and Biolex Therapeutics. As of March 2020, Bioventures Investors has made 32 investments. Their most recent investment was on November 12, 2019, when Sonomotion raised $10M. Bioventures Investors has had seven exits, the most notable of which include Enanta Pharmaceuticals, Phase Forward, and Spirus Medical. The company has raised a single venture fund, BioVentures Investors IV. This fund was announced on October 10, 2016 and raised a total of $87M.

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.